Chloé A.
- Country
- France
- Department
- Service de Diabétologie
Research Overview
- Evaluation of Clinical and Biological Response to Repeated Low-Dose Aldesleukin in Type 1 Diabetes Patients with Residual Insulin Secretion Post-Ciclosporin Therapy
- Efficacy and Safety of Teplizumab Versus Placebo in Stage 3 Type 1 Diabetes Patients Aged 1-25: A Randomized, Double-Blind, Phase 3 Trial
Data & Insights
Has run more than one trial at 1 of 71 partner sites.
Specializations
Autoimmune Disease Research
The investigator specializes in the study of type 1 diabetes, with particular emphasis on early-stage disease management and innovative therapeutic approaches for patients with newly diagnosed conditions.
- Recent-onset diabetes management
- Autoimmune response modulation
- Residual insulin secretion preservation
The research focus includes evaluating therapeutic responses in patients who maintain residual insulin production capabilities.
Immunotherapy Research
The investigator conducts studies involving interleukin-2 therapy, specifically exploring low-dose applications in autoimmune conditions. Their work examines immunological responses and regulatory T cell dynamics.
- Low-dose cytokine therapy
- Immune system modulation
- T-cell response patterns
Their expertise extends to examining biological responses to repeated immunotherapy administration protocols.
Therapeutic Innovation
The investigator explores combination therapy approaches, including the integration of immunosuppressive treatments with novel therapeutic strategies in early-stage diabetes management.
- Combined treatment protocols
- Early intervention strategies
- Treatment response monitoring
Their research encompasses the evaluation of therapeutic efficacy in preserving pancreatic function.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.